Vi-Uril may be available in the countries listed below.
Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Vi-Uril in the following countries:
International Drug Name Search
Treating certain skin conditions (eg, acne vulgaris, acne rosacea, seborrheic dermatitis). It may also be used for other conditions as determined by your doctor.
Rosula CLK Kit is a kit containing a sulfonamide antibiotic/keratolytic combination along with sunscreen. The wash works by killing sensitive bacteria on the skin. It also helps to loosen and shed hard, scaly skin. The sunscreen helps to prevent sunburn.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Rosula CLK Kit. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Rosula CLK Kit. Because little, if any, of Rosula CLK Kit is absorbed into the blood, the risk of it interacting with another medicine is low.
Ask your health care provider if Rosula CLK Kit may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Rosula CLK Kit as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Rosula CLK Kit.
All medicines may cause side effects, but many people have no, or minor side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Mild redness or peeling; minor skin irritation
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); fever, chills, or sore throat; purple or brownish spots on the skin; red, swollen, blistered, or peeling skin; severe or persistent skin irritation; unusual tiredness or weakness; yellowing of the skin or eyes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Rosula CLK side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center ( http://www.aapcc.org), or emergency room immediately.
Store Rosula CLK Kit at room temperature, between 59 and 77 degrees F (15 and 25 degrees C). Do not freeze. Store away from heat and light. Keep Rosula CLK Kit out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Rosula CLK Kit. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Caspofungin diacetate (a derivative of Caspofungin) is reported as an ingredient of Intravenous Infusion Cancidas in the following countries:
International Drug Name Search
Cibacalcin may be available in the countries listed below.
Calcitonin is reported as an ingredient of Cibacalcin in the following countries:
International Drug Name Search
Relieving eye redness and dryness due to minor eye irritation and preventing the eye from becoming more irritated. It may also be used for other conditions as determined by your doctor.
Refresh Redness Relief Drops are a decongestant and lubricant combination. The decongestant works by constricting blood vessels in the eye, which helps relieve redness. The lubricant works by providing moisture to the eye, which helps relieve dryness and protects the eye from becoming more irritated.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Refresh Redness Relief Drops. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Refresh Redness Relief Drops. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Refresh Redness Relief Drops may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Refresh Redness Relief Drops as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Refresh Redness Relief Drops.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Burning or stinging of the eye; temporary increase in pupil size.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); eye pain; new or worsening eye irritation; vision changes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Refresh Redness Relief side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.
Store Refresh Redness Relief Drops at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Refresh Redness Relief Drops out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Refresh Redness Relief Drops. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Generic Name: olanzapine (oral) (oh LANZ a peen)
Brand Names: ZyPREXA, ZyPREXA Zydis
Olanzapine is an antipsychotic medication that affects chemicals in the brain.
Olanzapine is used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression) in adults and children who are at least 13 years old.
Olanzapine is sometimes used together with other antipsychotic medications or antidepressants.
Olanzapine may also be used for purposes not listed in this medication guide.
You may gain weight or have high cholesterol and triglycerides (types of fat) while taking this medicine, especially if you are a teenager. Your blood may need to be tested often. Visit your doctor regularly.
Olanzapine can cause high blood sugar (hyperglycemia). If you are diabetic, check your blood sugar levels on a regular basis while you are taking olanzapine.
Treatments for depression are getting better everyday and there are things you can start doing right away.
Avoid getting up too fast from a sitting or lying position, or you may feel dizzy. Get up slowly and steady yourself to prevent a fall.
To make sure you can safely take olanzapine, tell your doctor if you have any of these other conditions:
heart disease, high or low blood pressure;
a history of low white blood cell (WBC) counts;
high cholesterol or triglycerides;
a history of heart failure, heart attack, or stroke;
a history of breast cancer;
seizures or epilepsy;
diabetes;
an enlarged prostate or difficulty urinating;
bowel problems; or
narrow-angle glaucoma.
The olanzapine orally disintegrating tablet (Zyprexa Zydis) may contain phenylalanine. Talk to your doctor before using this form of olanzapine if you have phenylketonuria (PKU).
Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label. Your doctor may occasionally change your dose to make sure you get the best results.
Olanzapine can be taken with or without food.
Olanzapine is usually taken once a day. Olanzapine may be only part of a complete program of treatment that also includes counseling and other psychological support programs. Follow your doctor's instructions.
To take olanzapine orally disintegrating tablets (Zyprexa Zydis):
Keep the tablet in its blister pack until you are ready to take it. Open the package and peel back the foil from the tablet blister. Do not push a tablet through the foil or you may damage the tablet.
Using dry hands, remove the tablet and place it in your mouth. It will begin to dissolve right away.
Do not swallow the tablet whole. Allow it to dissolve in your mouth without chewing.
Swallow several times as the tablet dissolves. If desired, you may drink liquid to help swallow the dissolved tablet.
Olanzapine can cause high blood sugar (hyperglycemia). If you are diabetic, check your blood sugar levels on a regular basis while you are taking olanzapine.
You may gain weight or have high cholesterol and triglycerides (types of fat) while taking this medicine, especially if you are a teenager. Your blood may need to be tested often. Visit your doctor regularly.
If you are taking a combination of drugs, use all medications as directed by your doctor. Read the medication guide or patient instructions provided with each medication. Do not change your doses or medication schedule without your doctor's advice.
See also: Olanzapine dosage (in more detail)
Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
Avoid getting up too fast from a sitting or lying position, or you may feel dizzy. Get up slowly and steady yourself to prevent a fall.
very stiff (rigid) muscles, high fever, tremors, sweating, confusion, fast or uneven heartbeats, slow heart rate, feeling like you might pass out;
twitching or uncontrollable movements of your eyes, lips, tongue, face, arms, or legs;
trouble speaking or swallowing;
dry mouth, thirst, feeling very hot (with or without sweating), urinating less than usual or not at all;
high blood sugar (increased thirst, loss of appetite, fruity breath odor, increased urination, drowsiness, dry skin, nausea, and vomiting);
sudden numbness or weakness, confusion, or problems with vision, speech, or balance;
fever, chills, body aches, flu symptoms, sores in your mouth and throat;
swelling in your hands or feet;
changes in personality, unusual thoughts or behavior, hallucinations, or thoughts about hurting yourself; or
upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).
Less serious side effects may include:
weight gain (more likely in teenagers), increased appetite;
headache, dizziness, drowsiness, feeling tired or restless;
memory problems;
stomach pain, constipation, loss of bladder control;
back pain, pain in your arms or legs;
numbness or tingly feeling;
breast swelling or discharge (in women or men); or
missed menstrual periods.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for Bipolar Disorder:
Oral (monotherapy):
Initial dose: 10 to 15 mg orally once a day.
Maintenance dose: 5 to 20 mg orally once a day.
Maximum dose: 20 mg orally once a day.
Oral (combination therapy with lithium or valproate):
Initial dose: 10 mg orally once a day.
Maintenance dose: 5 to 20 mg orally once a day.
Maximum dose: 20 mg orally once a day.
Injection:
Initial dose: 10 mg IM once.
Recommended dose: 10 mg IM once. A lower dose of 5 mg or 7.5 mg may be considered when clinical factors warrant. If agitation warranting additional intramuscular doses persists following the initial dose, subsequent doses up to 10 mg may be given. The efficacy of repeated doses of IM olanzapine in agitated patients has not been systematically evaluated in controlled clinical trials.
The safety of total daily dose greater than 30 mg (or 10 mg injections given more frequently than 2 hours after the initial dose and four hours after the second dose) has not been evaluated in clinical trials.
Dosage range: 2.5 mg to 10 mg IM once.
If ongoing olanzapine therapy is clinically indicated, oral olanzapine may be initiated in a range of 5 to 20 mg per day as soon as clinically appropriate.
Usual Adult Dose for Schizophrenia:
Oral:
Initial dose: 5 to 10 mg orally once a day.
Maintenance dose: 10 mg orally once a day.
Maximum dose: 20 mg orally once a day.
There are two olanzapine intramuscular formulations with different dosing schedules. Olanzapine intramuscular (10 mg/vial) is a short-acting formulation and should not be confused with olanzapine extended release injectable suspension (Brand Name: RELPREVV).
Short-acting Injection:
Initial dose: 10 mg IM once.
Recommended dose: 10 mg IM once. A lower dose of 5 mg or 7.5 mg may be considered when clinical factors warrant. If agitation warranting additional intramuscular doses persists following the initial dose, subsequent doses up to 10 mg may be given. The efficacy of repeated doses of IM olanzapine in agitated patients has not been systematically evaluated in controlled clinical trials.
The safety of total daily dose greater than 30 mg (or 10 mg injections given more frequently than 2 hours after the initial dose and four hours after the second dose) has not been evaluated in clinical trials.
Dosage range: 2.5 mg to 10 mg IM once.
If ongoing olanzapine therapy is clinically indicated, oral olanzapine may be initiated in a range of 5 to 20 mg per day as soon as clinically appropriate.
Extended Release Injectable Suspension:
The extended release injectable suspension is intended for deep intramuscular gluteal injection only and should not be administered intravenously or subcutaneously.
Tolerability should be established with oral olanzapine prior to initiating treatment with the extended release injectable suspension.
The efficacy of olanzapine extended release injectable suspension has been demonstrated within the range of 150 mg to 300 mg administered every 2 weeks and with 405 mg administered every 4 weeks.
Recommended Dosing for Olanzapine Extended Release Injectable Suspension Based on Correspondence to Oral Olanzapine Doses:
1) If the target oral olanzapine dose is 10 mg/day, then the dosing during the first 8 weeks is 210 mg/2 weeks or 405 mg/4 weeks, and the maintenance dose after 8 weeks is 150 mg/2 weeks or 300 mg/4 weeks.
2) If the target oral olanzapine dose is 15 mg/day, then the dosing during the first 8 weeks is 300 mg/2 weeks, and the maintenance dose after 8 weeks is 210 mg/2 weeks or 405 mg/4 weeks.
3) If the target oral olanzapine dose is 20 mg/day, then the dosing during the first 8 weeks is 300 mg/2 weeks, and the maintenance dose after 8 weeks is 300 mg/2 weeks.
Olanzapine extended release injectable suspension doses greater than 405 mg every 4 weeks or 300 mg every 2 weeks have not been evaluated in clinical trials.
For patients who are debilitated, who have a predisposition to hypotensive reactions, who otherwise exhibit a combination of factors that may result in slower metabolism of olanzapine (e.g., nonsmoking female patients 65 years of age or older), or who may be more pharmacodynamically sensitive to olanzapine:
Recommended starting dose: 150 mg/4 weeks
When indicated, dose escalation should be undertaken with caution in these patients.
Maintenance: Although no controlled studies have been conducted to determine how long patients should be treated with olanzapine extended release injectable suspension, efficacy has been demonstrated over a period of 24 weeks in patients with stabilized schizophrenia. Patients should be periodically reassessed to determine the need for continued treatment.
Usual Geriatric Dose for Bipolar Disorder:
Oral:
Initial dose: 5 mg orally once a day if debilitated or predisposed to hypotension.
Maintenance dose: May increase cautiously.
Injection:
Initial Dose: 5 mg IM once. A lower dose of 2.5 mg per injection should be considered for patients who otherwise may be debilitated, predisposed to hypotensive reactions, or who are more pharmacodynamically sensitive to olanzapine.
Usual Geriatric Dose for Schizophrenia:
Oral:
Initial dose: 5 mg orally once a day if debilitated or predisposed to hypotension.
Maintenance dose: May increase cautiously.
There are two olanzapine intramuscular formulations with different dosing schedules. Olanzapine intramuscular (10 mg/vial) is a short-acting formulation and should not be confused with olanzapine extended release injectable suspension (Brand Name: RELPREVV).
Short-acting Injection:
Initial Dose: 5 mg IM once. A lower dose of 2.5 mg per injection should be considered for patients who otherwise may be debilitated, predisposed to hypotensive reactions, or who are more pharmacodynamically sensitive to olanzapine.
Extended Release Injectable Suspension:
For patients who are debilitated, who have a predisposition to hypotensive reactions, who otherwise exhibit a combination of factors that may result in slower metabolism of olanzapine (e.g., nonsmoking female patients 65 years of age or older), or who may be more pharmacodynamically sensitive to olanzapine:
Recommended starting dose: 150 mg/4 weeks
When indicated, dose escalation should be undertaken with caution.
Maintenance: Although no controlled studies have been conducted to determine how long patients should be treated with olanzapine extended release injectable suspension, efficacy has been demonstrated over a period of 24 weeks in patients with stabilized schizophrenia. Patients should be periodically reassessed to determine the need for continued treatment.
Usual Pediatric Dose for Schizophrenia:
8 to 12 years (Limited data available):
Initial: 2.5 to 5 mg once daily; increase dose in 2.5 or 5 mg increments at weekly intervals to target dose of 10 mg once daily; maximum dose: 20 mg/day.
13 to 17 years old:
Initial dose: 2.5 to 5 mg orally once a day
Maintenance dose: 10 mg orally once a day
Efficacy in adolescents with schizophrenia has been demonstrated based on a flexible dose range of 2.5 mg to 20 mg/day in clinical trials. When dosage adjustments are necessary, dose increments/decrements of 2.5 mg or 5 mg are recommended.
The safety and effectiveness of doses above 20 mg/day have not been evaluated in clinical trials.
Maintenance: The efficacy of olanzapine for the maintenance treatment of schizophrenia in the adolescent population has not been systematically evaluated. However, maintenance efficacy can be extrapolated from adult data along with comparisons of olanzapine pharmacokinetic parameters in adult and adolescent patients. It is generally recommended that responding patients be continued beyond the acute response, but at the lowest dose needed to maintain remission. Patients should be periodically reassessed to determine the need for maintenance treatment.
Usual Pediatric Dose for Bipolar Disorder:
4 to 5 years: Limited data available: Initial: 1.25 mg orally once daily; increase at weekly intervals according to response and tolerability to target dose: 10 mg/day.
6 to 12 years: Limited data available: Initial: 2.5 mg orally once daily; increase dose in 2.5 or 5 mg increments at weekly intervals to target dose of 10 mg once daily; maximum dose: 20 mg/day.
13 to 17 years old:
Initial dose: 2.5 mg to 5 mg orally once a day
Maintenance dose: 10 mg orally once a day
Efficacy in adolescents with bipolar I disorder (manic or mixed episodes) was demonstrated based on a flexible dose range of 2.5 to 20 mg/day in clinical trials. When dosage adjustments are necessary, dose increments/decrements of 2.5 or 5 mg are recommended.
The safety and effectiveness of doses above 20 mg/day have not been evaluated in clinical trials.
Maintenance: The efficacy of olanzapine for the maintenance treatment of bipolar I disorder in the adolescent population has not been evaluated. However, maintenance efficacy can be extrapolated from adult data along with comparisons of olanzapine pharmacokinetic parameters in adult and adolescent patients. It is generally recommended that responding patients be continued beyond the acute response, but at the lowest dose needed to maintain remission. Patients should be periodically reassessed to determine the need for maintenance treatment.
Usual Pediatric Dose for Anorexia Nervosa:
9 years and older: (Limited data available): 1.25 to 2.5 mg orally once daily has been shown in one small trial and several case reports to improve BMI and other disease related symptoms (e.g., eating attitudes, anxiety); another case series used initial doses of 2.5 mg once daily and final doses of 5 mg to 10 mg once daily; reported range: 1.25 to 12.5 mg/day; however, it has been suggested that higher doses (greater than 2.5 mg once daily) may not be associated with greater efficacy. Further studies are needed.
Usual Pediatric Dose for Tourette's Syndrome:
Tourette syndrome, tic disorder:
7 years and older: Limited data available:
Patient weight less than 40 kg: Initial: 2.5 mg orally every other day for 3 days, increase to 2.5 mg every day for remainder of week; increase to 5 mg/day by second week if needed; then increase in 5 mg increments at weekly intervals as tolerated; maximum dose: 20 mg/day
Patient weight greater than 40 kg: Initial: 2.5 mg every day for 3 days; increase to 5 mg every day for remainder of week if needed, then increase in 5 mg increments at weekly intervals as tolerated; maximum dose: 20 mg/day
An open-label study of 10 pediatric patients (7 to 13 years of age) reported significant reductions in tic severity [Yale Global Tic Severity Scale (YGTSS)] from baseline at a mean final dose of 14.5 mg/day after 8 weeks of treatment. An open-label trial of 12 children and adolescents (7 to 14 years of age) reported a significant reduction (30%) in total tic severity (YGTSS) at a final mean dose of 11.3 mg/day (range: 2.5 to 20 mg/day).
Tell your doctor about all other medicines you use, especially:
heart or blood pressure medication;
carbamazepine (Carbatrol, Tegretol);
diazepam (Valium);
fluoxetine and olanzapine (Symbyax);
fluvoxamine (Luvox);
omeprazole (Prilosec);
rifampin (Rifater, Rifadin, Rifamate); or
a medication to treat Parkinson's disease including levodopa (Sinemet, Larodopa, Atamet), selegiline (Eldepryl, Emsam, Zelapar), pramipexole (Mirapex), ropinirole (Requip), and others.
This list is not complete and other drugs may interact with olanzapine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
See also: olanzapine side effects (in more detail)
Cholestagel may be available in the countries listed below.
UK matches:
Colesevelam is reported as an ingredient of Cholestagel in the following countries:
Colesevelam hydrochloride (a derivative of Colesevelam) is reported as an ingredient of Cholestagel in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Isoniazida Iqfarma may be available in the countries listed below.
Isoniazid is reported as an ingredient of Isoniazida Iqfarma in the following countries:
International Drug Name Search
ACT-3 may be available in the countries listed below.
Ibuprofen is reported as an ingredient of ACT-3 in the following countries:
International Drug Name Search
Apopril may be available in the countries listed below.
Captopril is reported as an ingredient of Apopril in the following countries:
International Drug Name Search
Derma may be available in the countries listed below.
Clindamycin dihydrogen phosphate (a derivative of Clindamycin) is reported as an ingredient of Derma in the following countries:
International Drug Name Search
Rec.INN
N06AX14
0066981-73-5
C21-H25-Cl-N2-O4-S
436
Antidepressant, tricyclic
Heptanoic acid, 7-[(3-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]-, S,S-dioxide
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Famotidin AbZ may be available in the countries listed below.
Famotidine is reported as an ingredient of Famotidin AbZ in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Rec.INN
A16AA04
0000060-23-1
C2-H7-N-S
77
Antidote
Ethanethiol, 2-amino-
International Drug Name Search
Glossary
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Thiovéol may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Tenoic Acid lithium salt (a derivative of Tenoic Acid) is reported as an ingredient of Thiovéol in the following countries:
International Drug Name Search
Tremexal may be available in the countries listed below.
Flutamide is reported as an ingredient of Tremexal in the following countries:
International Drug Name Search
Ketoconazol Juventus may be available in the countries listed below.
Ketoconazole is reported as an ingredient of Ketoconazol Juventus in the following countries:
International Drug Name Search
Omeprazol Aphar may be available in the countries listed below.
Omeprazole is reported as an ingredient of Omeprazol Aphar in the following countries:
International Drug Name Search
Shipkisanon may be available in the countries listed below.
Ciprofloxacin is reported as an ingredient of Shipkisanon in the following countries:
International Drug Name Search
Vérapamil Ratiopharm may be available in the countries listed below.
Verapamil hydrochloride (a derivative of Verapamil) is reported as an ingredient of Vérapamil Ratiopharm in the following countries:
International Drug Name Search
In the US, Arginine (arginine systemic) is a member of the following drug classes: in vivo diagnostic biologicals, oral nutritional supplements and is used to treat Diagnosis and Investigation and Dietary Supplementation.
US matches:
Rec.INN
0000074-79-3
C6-H14-N4-O2
174
Amino acid
Hepatoprotective agent
(S)-2-Amino-5-guanidinopentansäure
L-Arginine
International Drug Name Search
Glossary
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| DCIT | Denominazione Comune Italiana |
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Nistatina Lafedar may be available in the countries listed below.
Nystatin is reported as an ingredient of Nistatina Lafedar in the following countries:
International Drug Name Search
Ninlium may be available in the countries listed below.
Domperidone is reported as an ingredient of Ninlium in the following countries:
International Drug Name Search
Coroval may be available in the countries listed below.
Amlodipine besilate (a derivative of Amlodipine) is reported as an ingredient of Coroval in the following countries:
International Drug Name Search
Dopamol may be available in the countries listed below.
Paracetamol is reported as an ingredient of Dopamol in the following countries:
International Drug Name Search
Apo-Cefuroxime may be available in the countries listed below.
Cefuroxime axetil (a derivative of Cefuroxime) is reported as an ingredient of Apo-Cefuroxime in the following countries:
International Drug Name Search
Scherisolona may be available in the countries listed below.
Prednisolone is reported as an ingredient of Scherisolona in the following countries:
International Drug Name Search
Stesolid may be available in the countries listed below.
UK matches:
Diazepam is reported as an ingredient of Stesolid in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
Qari may be available in the countries listed below.
Rufloxacin hydrochloride (a derivative of Rufloxacin) is reported as an ingredient of Qari in the following countries:
International Drug Name Search
Losartan-Kalium TAD may be available in the countries listed below.
Losartan potassium salt (a derivative of Losartan) is reported as an ingredient of Losartan-Kalium TAD in the following countries:
International Drug Name Search
Gastrizol Plus may be available in the countries listed below.
Omeprazole is reported as an ingredient of Gastrizol Plus in the following countries:
International Drug Name Search
Rumin may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Calcium Acetate is reported as an ingredient of Rumin in the following countries:
Magnesium Oxide is reported as an ingredient of Rumin in the following countries:
Sodium Phosphate Monobasic (a derivative of Sodium Phosphate) is reported as an ingredient of Rumin in the following countries:
International Drug Name Search
Glimepibal may be available in the countries listed below.
Glimepiride is reported as an ingredient of Glimepibal in the following countries:
International Drug Name Search
Angicor may be available in the countries listed below.
Isosorbide Mononitrate is reported as an ingredient of Angicor in the following countries:
Nicorandil is reported as an ingredient of Angicor in the following countries:
International Drug Name Search
Cetor may be available in the countries listed below.
C1 Esterase Inhibitor, human is reported as an ingredient of Cetor in the following countries:
International Drug Name Search
Alprazolam Labesfal may be available in the countries listed below.
Alprazolam is reported as an ingredient of Alprazolam Labesfal in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
In the US, Ridaura (auranofin systemic) is a member of the drug class antirheumatics and is used to treat Felty's Syndrome, Pemphigus, Psoriatic Arthritis and Rheumatoid Arthritis.
US matches:
Auranofin is reported as an ingredient of Ridaura in the following countries:
International Drug Name Search
Viartril-S may be available in the countries listed below.
Glucosamine sulfate (a derivative of Glucosamine) is reported as an ingredient of Viartril-S in the following countries:
International Drug Name Search
Oxybuprocaine Minims may be available in the countries listed below.
Oxybuprocaine hydrochloride (a derivative of Oxybuprocaine) is reported as an ingredient of Oxybuprocaine Minims in the following countries:
International Drug Name Search
Vifazolin may be available in the countries listed below.
Cefazolin sodium salt (a derivative of Cefazolin) is reported as an ingredient of Vifazolin in the following countries:
International Drug Name Search
Etosuximida Faes may be available in the countries listed below.
Ethosuximide is reported as an ingredient of Etosuximida Faes in the following countries:
International Drug Name Search
Decalcit may be available in the countries listed below.
Calcium Phosphate is reported as an ingredient of Decalcit in the following countries:
Colecalciferol is reported as an ingredient of Decalcit in the following countries:
International Drug Name Search
See also: Generic Optiray 240, Generic Optiray 300, Generic Optiray 320
Optiray 350 is a brand name of ioversol, approved by the FDA in the following formulation(s):
No. There is currently no therapeutically equivalent version of Optiray 350 available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Optiray 350. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
There are no current U.S. patents associated with Optiray 350.
Pediaphyllin PL may be available in the countries listed below.
Theophylline is reported as an ingredient of Pediaphyllin PL in the following countries:
International Drug Name Search
Vomiseda may be available in the countries listed below.
Meclozine dihydrochloride (a derivative of Meclozine) is reported as an ingredient of Vomiseda in the following countries:
International Drug Name Search
Lincopharm may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Lincomycin hydrochloride monohydrate (a derivative of Lincomycin) is reported as an ingredient of Lincopharm in the following countries:
International Drug Name Search
Verapamilo Perugen may be available in the countries listed below.
Verapamil is reported as an ingredient of Verapamilo Perugen in the following countries:
International Drug Name Search
Daipin may be available in the countries listed below.
Methylscopolamine methylsulfate (a derivative of Methylscopolamine) is reported as an ingredient of Daipin in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Phenylbutazone is reported as an ingredient of Butequine in the following countries:
International Drug Name Search
des-ox-i-MET-a-sone
In the U.S.
In Canada
Available Dosage Forms:
Therapeutic Class: Corticosteroid, Strong
Pharmacologic Class: Adrenal Glucocorticoid
Desoximetasone topical is used to help relieve redness, itching, swelling, or other discomfort caused by skin conditions. desoximetasone is a corticosteroid (cortisone-like medicine or steroid).
desoximetasone is available only with your doctor's prescription.
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For desoximetasone, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to desoximetasone or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of desoximetasone in children 10 years of age or older. However, because of desoximetasone's toxicity, it should be used with caution. Children and teenagers who must use desoximetasone should be checked often by their doctor since desoximetasone topical may be absorbed through the skin and can affect growth or cause other unwanted effects. Safety and efficacy have not been established in children younger than 10 years of age.
No information is available on the relationship of age to the effects of desoximetasone topical in geriatric patients.
| Pregnancy Category | Explanation | |
|---|---|---|
| All Trimesters | C | Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women. |
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
The presence of other medical problems may affect the use of desoximetasone. Make sure you tell your doctor if you have any other medical problems, especially:
Use desoximetasone exactly as directed by your doctor. Do not use it for any other condition without first checking with your doctor. desoximetasone may cause unwanted effects if it is used too much, because more of it is absorbed into the body through the skin.
Wash your hands with soap and water before and after using desoximetasone.
Be very careful not to get desoximetasone in your eyes. Wash your hands after using your finger to apply the medicine. If you accidentally get desoximetasone in your eyes, flush them with water.
Apply a thin layer of desoximetasone to the affected area of the skin. Rub it in gently.
Unless otherwise directed by your doctor, do not apply desoximetasone to open wounds, burns, or broken or inflamed skin.
desoximetasone should only be used for problems being treated by your doctor. Check with your doctor before using it for other problems, especially if you think that an infection may be present. desoximetasone should not be used to treat certain kinds of skin infections or serious problems, such as severe burns.
Do not bandage or otherwise wrap the skin being treated unless directed to do so by your doctor.
If your doctor has ordered an occlusive dressing (airtight covering, such as kitchen plastic wrap or a special patch) to be applied over desoximetasone, make sure you know how to apply it. Since occlusive dressings increase the amount of medicine absorbed through your skin and the possibility of side effects, use them only as directed. If you have any questions about this, check with your doctor.
The dose of desoximetasone will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of desoximetasone. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
If you miss a dose of desoximetasone, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.
Keep out of the reach of children.
Do not keep outdated medicine or medicine no longer needed.
Ask your healthcare professional how you should dispose of any medicine you do not use.
It is very important that your doctor check your or your child's progress at regular visits for any problems or unwanted effects that may be caused by desoximetasone.
If your symptoms do not improve within a few days, or if it become worse, check with your doctor.
After applying desoximetasone to the skin of your child, watch the child carefully to make sure that he or she does not get any of the medicine in the eyes or mouth. desoximetasone can cause serious side effects, especially in children, if it gets into the mouth and is swallowed.
Using too much of desoximetasone or using it for a long time may increase your risk of having adrenal gland problems. The risk is greater for children and for patients who use large amounts for a long time. Talk to your doctor if you or your child have more than one of these symptoms while you are using desoximetasone: blurred vision; dizziness or fainting; fast, irregular, or pounding heartbeat; increased thirst or urination; irritability; or unusual tiredness or weakness.
Stop using desoximetasone and check with your doctor right away if you or your child have a skin rash, burning, stinging, swelling, or irritation on the skin.
Avoid using tight-fitting diapers or plastic pants on a child if desoximetasone is being used on the child's diaper area. Plastic pants and tight-fitting diapers may increase the chance of absorption of the medicine through the skin and the chance of side effects.
Do not use cosmetics or other skin care products on the treated skin areas.
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur:
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
See also: desoximetasone Topical application side effects (in more detail)
The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.
